David Grand, Bazelet's Chief Research Officer

"We are breeding from varieties that are registered and approved globally"

Three of Bazelet Health Systems' industrial cannabis genetics were top performers in the "2021 Fiber and Dual-Purpose Strip Trials" conducted by Cornell University in Geneva, New York. According to Cornell's report on the trials, Bazelet genetics outperformed all others, highlighting unmatched seed weight, germination rates, plant density per ft2, and plant height. 

"We are breeding from varieties that are registered and approved globally, including by the EU and AOSCA, as well as new genetics that utilize [CRISPR]Cas9 to further advance our unique cannabis plants and expect these advances will transform global food supply chains," said David Grand, Bazelet's Chief Research Officer.

The report indicates Bazelet genetics had a seed weight more than 20% greater than the next place finisher and seed germination rates reached 88%. As a finished plant, a stand count of 20 plants per ft2 was reported, almost two times more than others and the three Bazelet plant varieties grew to heights 1.5x taller than other varieties.

Michael Elzufon, Bazelet's Chief Strategy Officer added "Our participation in the Cornell Trails emphasizes our unwavering conviction regarding the development of reliable, safe, legal, profitable cannabis. They also further validate years of Bazelet's scientific work that is leading to next-generation super foods derived from therapeutic non-psychoactive cannabis."

For more information:
Phone: +972-72-22-88-646 
Fax: +972-4-858-16-71

Publication date:

Receive the daily newsletter in your email for free | Click here

Other news in this sector:

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber